Welcome to our dedicated page for Phathom Pharmaceuticals SEC filings (Ticker: PHAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Phathom is a biopharmaceutical company focused on gastrointestinal (GI) diseases, and its filings offer detailed information on VOQUEZNA (vonoprazan) commercialization, clinical programs, and corporate activity.
Through current reports on Form 8-K, Phathom reports material events such as quarterly and interim financial results, clinical trial milestones, leadership changes, and key scientific publications. For example, the company has used Form 8-K to announce financial results for specific quarters, publication of additional analyses from the Phase 3 pHalcon-NERD-301 trial in Non-Erosive GERD, and initiation of the Phase 2 pHalcon-EoE-201 study in eosinophilic esophagitis.
Filings also document capital markets transactions, including underwritten public offerings of common stock and pre-funded warrants, and provide details on the intended use of proceeds for working capital, commercialization, and research and development expenses. Disclosures about executive appointments and compensation arrangements, such as the appointment of a Chief Financial and Business Officer, are likewise reported in 8-K filings.
On Stock Titan, these SEC documents are complemented by AI-powered summaries that highlight the key points of lengthy filings, helping readers quickly understand topics such as operating performance, clinical trial updates, and corporate governance changes. Users can monitor real-time updates from EDGAR, review quarterly and annual reports when available, and examine current reports for insights into Phathom’s GI-focused business. This page serves as a central resource for investors and researchers who want to analyze PHAT’s official disclosures alongside concise AI-generated explanations.
Steven L. Basta, President and CEO and a director of Phathom Pharmaceuticals, Inc. (PHAT), reported stock and derivative transactions on Form 4. On 09/25/2025 he acquired 90,000 shares of common stock upon vesting of performance stock units granted 04/03/2025; those 90,000 shares were reported as acquired at $0 and increased his direct beneficial ownership to 90,000 shares. The filing also shows the surrender of 48,375 shares to the issuer to cover tax withholding at a price of $11.66 per share, leaving 41,625 shares after that disposition. The reporting person holds 270,000 shares underlying performance stock units after the reported vesting event, reflecting a grant of 360,000 PSUs on 04/03/2025 of which 90,000 vested due to achievement of a stock-price hurdle. The remaining PSUs vest upon future stock-price hurdles through four years from the grant, subject to continued service.
Insider transaction summary for Phathom Pharmaceuticals (PHAT): On 09/05/2025 Robert Charles Breedlove, listed as Principal Accounting Officer and an officer/director, disposed of 461 shares of Phathom common stock at $12.09 per share to satisfy tax withholding obligations arising from the settlement of restricted stock units. After the reported sale, Mr. Breedlove beneficially owned 47,931 shares directly and 6,945.4 shares indirectly through a 401(k) account. The Form 4 was signed on 09/09/2025 and indicates the transaction code S(1) with the provided explanation that the sale was to cover tax withholding on RSU settlement.
Phathom Pharmaceuticals (PHAT) received a joint Schedule 13G/A filed by a group of Carlyle-related entities and Abingworth entities disclosing shared beneficial ownership of 3,496,808 shares of Phathom common stock, representing 4.9% of the class based on 70,943,708 shares outstanding as of August 4, 2025. The filing lists the reporting persons, their jurisdictions, and that Abingworth Bioventures 8 LP holds 2,061,702 shares and Abingworth Bioventures VII LP holds 1,435,106 shares of record. The statement notes that, solely due to dilution from additional issuances by the issuer, the Reporting Persons no longer beneficially own more than 5% of outstanding common stock. Signatures from authorized representatives for each reporting entity and a referenced Joint Filing Agreement are included.
Schedule 13G/A filings disclose that Integrated Core Strategies (US) LLC reported beneficial ownership of 3,588,650 shares of Phathom Pharmaceuticals common stock, representing 5.1% of the class, and that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each reported beneficial ownership of 4,160,515 shares, representing 5.9% of the class. The filings state these shares are held with shared voting and dispositive power and identify a Joint Filing Agreement dated August 22, 2025. The registrants certify the holdings were not acquired to change or influence control of the issuer.
Amendment No. 10 to a Schedule 13D updates disclosures about holdings in Phathom Pharmaceuticals, Inc. (Common Stock, CUSIP 71722W107). Multiple Frazier Life Sciences funds report shared voting and dispositive power over specified blocks of common stock, with holdings calculated using 70,943,708 shares outstanding as of August 4, 2025. Key positions disclosed include Frazier Life Sciences IX, L.P. with 5,827,415 shares (8.2%), Frazier Life Sciences Public Fund, L.P. with 4,234,991 shares (6.0%), and individual reporting persons James N. Topper and Patrick J. Heron with aggregate beneficial ownerships of 5,985,327 (8.6%) and 5,901,756 (8.4%), respectively. The amendment clarifies prior attributions of ownership to certain investment committee members and corrects overstated beneficial ownership. It also discloses warrants held by certain funds to purchase additional shares, subject to a 19.99% exercise limitation. The filing incorporates a Joint Filing Agreement as an exhibit.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported beneficial ownership of 3,762,044 shares of Phathom Pharmaceuticals, Inc. (PHAT), representing 5.3% of the outstanding common stock, via a Schedule 13G filed in connection with an 08/11/2025 event. The filing shows shared voting and dispositive power over the disclosed shares and includes a joint filing agreement as Exhibit I. Signatures on the filing were provided by Gil Raviv on behalf of the two management entities and by Israel A. Englander, dated 08/12/2025.
The filing includes a certification that the securities were not acquired to change or influence control of Phathom. All ownership figures and classifications are provided directly on the cover pages and in Item 4 of the Schedule 13G.
Phathom Pharmaceuticals reported a Form 4 filing on June 28, 2025, disclosing stock option grants to Anne Marie Cook, the company's Chief Legal Officer & Corporate Secretary.
Key transaction details:
- Granted 210,000 stock options to purchase common stock
- Exercise price set at $9.47 per share
- Grant date: June 23, 2025
- Expiration date: June 22, 2035
The options follow a 4-year vesting schedule: 25% vests on June 23, 2026, with the remainder vesting in equal monthly installments over the following three years, contingent on continuous service. This grant appears to be part of the company's executive compensation program.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
